,
Boost Fertility

Solving the $49B Infertility Crisis

About this Event

Infertility is now considered a disease and it takes a significant emotional toll on couples desperate to conceive. While some couples can afford the tens of thousands of dollars required to undergo IVF, most can’t, and for them, options are extremely limited.

Boost Fertility is on a mission to ensure that anyone who wants clinical-grade infertility treatment can get it by making it affordable and available for all. Based on the work of a world leading motility expert, Boost has developed a patented device that optimizes a non-invasive fertility treatment called IUI which has two key benefits compared to IVF:

1. It is 10 times more affordable
2. It is 100 times less invasive

IUI doesn’t require the couple to go to a specialized fertility clinic and go through a long, painful, and expensive process that involves two minor surgeries, multiple injections, and strong medication. Any qualified health care provider can perform Boost IUI in their office with no more than 30 minutes of work.

Boost Fertility is the world’s first truly scalable infertility treatment and thus represents a significant breakthrough that will make a highly effective infertility treatment available to all, opening up a global market estimated to be worth $49B by 2030.

Please watch our Fireside Chat with Boost Fertility CEO, Daniel Wilson, to hear how their patented device is poised to make Boost IUI the first line of treatment in the worldwide battle against infertility.

Video On Demand

– Recorded

January 27

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.